BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The 4th Annual Gene Therapy for Ophthalmic Disorders Summit is
  the industry-leading\, industry-focused forum for learning how to valida
 te novel administration routes to the eye\, extrapolate effectively from 
 preclinical models to inform safety and efficacy and define relevant endp
 oints for clinical trials.\n\nAcross 3 days of in-depth case studies\, ne
 w data\, and focused group discussions\, hear from and engage with the li
 kes of Janssen\, Adverum Biotechnologies\, Spark Therapeutics\, SparingVi
 sion\, AbbVie\, and the RD Fund. As well as leveraging insights from thes
 e talks and panels: participate in breakout discussions\, utilize Q and A
  time built into talks\, and meet and learn from ophthalmic gene therapy 
 leaders during our 5+ hours of dedicated networking time.\n\nThis Summit 
 Will Bring Together Leading Voices on:\n\n- Defining Relevant and Meaning
 ful EndpointsInvestigate the latest trends in endpoint development and re
 gulation\, understand their applicability in animal model studies to clin
 ical trials\, and discuss the need for validated novel endpoints\, with k
 ey insights from Adverum Biotechnologies and SparingVision.\n\n- Levellin
 g up the Translatability of Preclinical ModelsAddress the best practices 
 in animal model selection and development\, optimize the clinical relevan
 cy of animal model studies\, and leverage the latest retinal organoid dev
 elopments\, with expert sessions hosted by Atsena Therapeutics and MeiraG
 Tx.\n\n- Exploring Different Delivery Methods to the Front and Back of th
 e EyeTake a deep dive into the suprachoroidal route\, overcome the AAV ca
 rgo capacity challenge with novel administration methods\, and hear the l
 atest updated on robotics-assisted subretinal delivery\, with exciting di
 scussions from Clearside Biomedical and Splice Bio.\n\n- Understanding th
 e Immune and Inflammatory Responses to Ocular Gene TherapiesHow can impro
 ved promoters and enhancers deliver genes effectively without triggering 
 the immune response? Which preclinical models are best suited to test the
  various variables associated with GTAU? What are the latest trends in im
 munosuppressant regimens being used in the field? Let AGTC and Kriya Ther
 apeutics answer these questions\, and many more.\n\n- Leveraging Insights
  from Ophthalmology-Focused Venture CapitalDiscover the current investmen
 t landscape for gene therapy in the ophthalmology field\, and understand 
 what venture capital investors are looking for when it comes to developin
 g preclinical\, clinical\, and manufacturing packages in the most fruitfu
 l\, cost-effective manner\, with key insights from the RD Fund and Syncon
 a.\n\nFind out more in our event guide - https://ter.li/65eeyd\n
DTEND:20231005T170000
DTSTAMP:20260512T232950Z
DTSTART:20231003T080000
LOCATION:The Westin Waltham Boston\, 70\, 3rd Avenue\, Waltham\, Middlesex
  County\, 02451\,
SEQUENCE:0
SUMMARY:The 4th Annual Gene Therapy for Ophthalmic Disorders Summit is the
  industry-leading\, industry-focused forum for learning how to validate n
 ovel admi...
UID:e08c931d-03aa-4925-822b-afaab613b233
END:VEVENT
END:VCALENDAR